These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22019955)

  • 1. Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis.
    Miller E; Walczak A; Saluk J; Ponczek MB; Majsterek I
    Clin Biochem; 2012 Jan; 45(1-2):26-30. PubMed ID: 22019955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier.
    Shimizu F; Tasaki A; Sano Y; Ju M; Nishihara H; Oishi M; Koga M; Kawai M; Kanda T
    PLoS One; 2014; 9(3):e92872. PubMed ID: 24686948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
    Choi IY; Lee P; Adany P; Hughes AJ; Belliston S; Denney DR; Lynch SG
    Mult Scler; 2018 Jul; 24(8):1029-1038. PubMed ID: 28569645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of cytotoxic Eomes-expressing CD4
    Raveney BJE; Sato W; Takewaki D; Zhang C; Kanazawa T; Lin Y; Okamoto T; Araki M; Kimura Y; Sato N; Sano T; Saito Y; Oki S; Yamamura T
    Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of endogenous antiradical protective system in multiple sclerosis.
    Davitashvili D; Beridze M; Shakarishvili R; Kiziria M; Sanikidze T
    Georgian Med News; 2012 Apr; (205):11-9. PubMed ID: 22665726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum miR-34a-5p, miR-103a-3p, and miR-376a-3p as possible biomarkers of conversion from relapsing-remitting to secondary progressive multiple sclerosis.
    Agostini S; Mancuso R; Citterio LA; Caputo D; Oreni L; Nuzzi R; Pasanisi MB; Rovaris M; Clerici M
    Neurobiol Dis; 2024 Oct; 200():106648. PubMed ID: 39181188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
    Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J
    J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication.
    Festoff BW; Li C; Woodhams B; Lynch S
    J Neurol Sci; 2012 Dec; 323(1-2):61-5. PubMed ID: 22967748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A blood-based metabolomics test to distinguish relapsing-remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application.
    Yeo T; Sealey M; Zhou Y; Saldana L; Loveless S; Claridge TDW; Robertson N; DeLuca G; Palace J; Anthony DC; Probert F
    Sci Rep; 2020 Jul; 10(1):12381. PubMed ID: 32709911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.
    Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M
    Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albumin and Protein Oxidation are Predictors that Differentiate Relapsing-Remitting from Progressive Clinical Forms of Multiple Sclerosis.
    Oliveira SR; Kallaur AP; Reiche EMV; Kaimen-Maciel DR; Panis C; Lozovoy MAB; Morimoto HK; Maes M; Dichi I; Simão ANC
    Mol Neurobiol; 2017 May; 54(4):2961-2968. PubMed ID: 27026183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy.
    Elovaara I; Ukkonen M; Leppäkynnäs M; Lehtimäki T; Luomala M; Peltola J; Dastidar P
    Arch Neurol; 2000 Apr; 57(4):546-51. PubMed ID: 10768630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis.
    Pasquali L; Lucchesi C; Pecori C; Metelli MR; Pellegrini S; Iudice A; Bonuccelli U
    J Neuroimmunol; 2015 Jan; 278():53-9. PubMed ID: 25595252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index.
    de Bock L; Fraussen J; Villar LM; Álvarez-Cermeño JC; Van Wijmeersch B; van Pesch V; Stinissen P; Somers V
    Eur J Neurol; 2016 Apr; 23(4):722-8. PubMed ID: 26706657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis.
    Frisullo G; Nociti V; Iorio R; Patanella AK; Marti A; Caggiula M; Mirabella M; Tonali PA; Batocchi AP
    Cytokine; 2008 Oct; 44(1):22-5. PubMed ID: 18793860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis.
    Adalsteinsson E; Langer-Gould A; Homer RJ; Rao A; Sullivan EV; Lima CA; Pfefferbaum A; Atlas SW
    AJNR Am J Neuroradiol; 2003; 24(10):1941-5. PubMed ID: 14625214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum ROCK2, miR-300 and miR-450b-5p levels in two different clinical phenotypes of multiple sclerosis: Relation to patient disability and disease progression.
    Ibrahim SH; El-Mehdawy KM; Seleem M; El-Sawalhi MM; Shaheen AA
    J Neuroimmunol; 2020 Oct; 347():577356. PubMed ID: 32781341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis.
    Filion LG; Matusevicius D; Graziani-Bowering GM; Kumar A; Freedman MS
    Clin Immunol; 2003 Feb; 106(2):127-38. PubMed ID: 12672403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases.
    Brettschneider J; Jaskowski TD; Tumani H; Abdul S; Husebye D; Seraj H; Hill HR; Fire E; Spector L; Yarden J; Dotan N; Rose JW
    J Neuroimmunol; 2009 Dec; 217(1-2):95-101. PubMed ID: 19879655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
    Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
    Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.